Base de dados : MEDLINE
Pesquisa : I01.615 [Categoria DeCS]
Referências encontradas : 17074 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1708 ir para página                         

  1 / 17074 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449795
[Au] Autor:Packer M; McMurray JJV; Krum H; Kiowski W; Massie BM; Caspi A; Pratt CM; Petrie MC; DeMets D; Kobrin I; Roux S; Swedberg K; ENABLE Investigators and Committees
[Ad] Endereço:Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas. Electronic address: milton.packer1526@baylorhealth.edu.
[Ti] Título:Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
[So] Source:JACC Heart Fail;5(5):317-326, 2017 May.
[Is] ISSN:2213-1787
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The objective of this clinical trial was to evaluate the long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure. BACKGROUND: Endothelin may play a role in heart failure, but short-term clinical trials with endothelin receptor antagonists have reported disappointing results. Long-term trials are lacking. METHODS: In 2 identical double-blind trials, we randomly assigned 1,613 patients with New York Heart Association functional class IIIb to IV heart failure and an ejection fraction <35% to receive placebo or bosentan (target dose 125 mg twice daily) for a median of 1.5 years. The primary outcome for each trial was clinical status at 9 months (assessed by the hierarchical clinical composite); the primary outcome across the 2 trials was death from any cause or hospitalization for heart failure. RESULTS: Bosentan did not influence clinical status at 9 months in either trial (p = 0.928 and p = 0.263). In addition, 321 patients in the placebo group and 312 patients in the bosentan group died or were hospitalized for heart failure (hazard ratio [HR]: 1.01; 95% confidence interval [CI]: 0.86 to 1.18; p = 0.90). The bosentan group experienced fluid retention within the first 2 to 4 weeks, as evidenced by increased peripheral edema, weight gain, decreases in hemoglobin, and an increased risk of hospitalization for heart failure, despite intensification of background diuretics. During follow-up, 173 patients died in the placebo group and 160 patients died in the bosentan group (HR: 0.94; 95% CI: 0.75 to 1.16). About 10% of the bosentan group showed meaningful increases in hepatic transaminases, but none had acute or chronic liver failure. CONCLUSIONS: Bosentan did not improve the clinical course or natural history of patients with severe chronic heart failure and but caused early and important fluid retention.
[Mh] Termos MeSH primário: Causas de Morte
Antagonistas dos Receptores de Endotelina/administração & dosagem
Insuficiência Cardíaca/tratamento farmacológico
Sulfonamidas/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Austrália
Doença Crônica
Relação Dose-Resposta a Droga
Método Duplo-Cego
Esquema de Medicação
Antagonistas dos Receptores de Endotelina/efeitos adversos
Europa (Continente)
Feminino
Insuficiência Cardíaca/diagnóstico
Insuficiência Cardíaca/mortalidade
Seres Humanos
Internacionalidade
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Morbidade
América do Norte
Prognóstico
Modelos de Riscos Proporcionais
Ensaios Clínicos Controlados Aleatórios como Assunto
Medição de Risco
Índice de Gravidade de Doença
Sulfonamidas/efeitos adversos
Análise de Sobrevida
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Endothelin Receptor Antagonists); 0 (Sulfonamides); Q326023R30 (bosentan)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29192048
[Au] Autor:Perry B
[Ad] Endereço:Brian Perry is chairman of the Strategic Advisory Board of Afrique One, honorary professor at the University of Edinburgh's College of Medicine and Veterinary Medicine and visiting professor at the University of Oxford's Nuffield College of Clinical Medicine.
[Ti] Título:We must tie equine welfare to international development.
[So] Source:Vet Rec;181(22):600-601, 2017 12.
[Is] ISSN:2042-7670
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Bem-Estar do Animal/organização & administração
Países em Desenvolvimento
Cavalos
Internacionalidade
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1136/vr.j5561


  3 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29192042
[Ti] Título:Disease surveillance in England and Wales, November 2017.
[So] Source:Vet Rec;181(22):585-589, 2017 12.
[Is] ISSN:2042-7670
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças dos Animais/epidemiologia
Surtos de Doenças/veterinária
Vigilância de Evento Sentinela/veterinária
[Mh] Termos MeSH secundário: Animais
Bovinos
Doenças dos Bovinos/epidemiologia
Galinhas
Inglaterra/epidemiologia
Órgãos Governamentais
Internacionalidade
Doenças das Aves Domésticas/epidemiologia
Sciuridae
Ovinos
Doenças dos Ovinos/epidemiologia
Suínos
Doenças dos Suínos/epidemiologia
País de Gales/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1136/vr.j5595


  4 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464909
[Au] Autor:Gmuca S; Xiao R; Brandon TG; Pagnini I; Wright TB; Beukelman T; Morgan EM; Weiss PF
[Ad] Endereço:Division of Rheumatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
[Ti] Título:Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches.
[So] Source:Arthritis Res Ther;19(1):84, 2017 May 02.
[Is] ISSN:1478-6362
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Enthesitis-related arthritis (ERA) is a specific subtype of juvenile idiopathic arthritis (JIA) defined according to the International League of Associations for Rheumatology (ILAR) criteria. We aimed to characterize the clinical features and treatment regimens in an inception cohort of children with ERA. METHODS: We performed a retrospective, cross-sectional, multicenter cohort study including subjects diagnosed with ERA between 1989 and 2012. Patients all fulfilled the ILAR criteria for ERA within 3 months of initial presentation to the rheumatology clinic. Differences in the prevalence of clinical criteria across study sites and by human leukocyte antigen (HLA)-B27 status were assessed using the Wilcoxon rank-sum or chi-square test, as appropriate. RESULTS: Two hundred thirty-four children met the inclusion criteria. Their median age at diagnosis was 11.6 years, and 59% were HLA-B27-positive. Sixty-nine percent had enthesitis and arthritis at the time of diagnosis. Seventy-eight percent had a pauciarticular onset. The prevalence of all ILAR criteria at diagnosis, except arthritis and acute anterior uveitis, differed significantly across sites (all p < 0.01). Medication use varied significantly across sites for children with peripheral arthritis (p < 0.001), but not for sacroiliitis or enthesitis only. Nonsteroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs were the most commonly prescribed treatments, with anti-TNF agents primarily being initiation for sacroiliitis. HLA-B27 positivity was associated with male sex, higher active joint count, sacroiliitis, and higher disease activity at disease onset. CONCLUSIONS: The majority of children had a pauciarticular onset, and several statistically significant clinical differences based on HLA-B27 status were identified. The observed heterogeneity in clinical presentation across sites reflects either true differences in patient populations or differences in how the ILAR criteria are being applied.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Antirreumáticos/uso terapêutico
Artrite Juvenil/diagnóstico
Artrite Juvenil/tratamento farmacológico
Internacionalidade
[Mh] Termos MeSH secundário: Adolescente
Artrite Juvenil/sangue
Criança
Estudos de Coortes
Estudos Transversais
Feminino
Antígeno HLA-B27/sangue
Seres Humanos
Masculino
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Antirheumatic Agents); 0 (HLA-B27 Antigen)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s13075-017-1297-x


  5 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778214
[Au] Autor:Card SE; Clark HD; Elizov M; Kassam N
[Ad] Endereço:Division of General Internal Medicine, University of Saskatchewan, Department of Internal Medicine, Royal University Hospital, 103 Hospital Drive, Saskatoon, SK, Canada. sharon.card@usask.ca.
[Ti] Título:The Evolution of General Internal Medicine (GIM)in Canada: International Implications.
[So] Source:J Gen Intern Med;32(5):576-581, 2017 May.
[Is] ISSN:1525-1497
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:General internal medicine (GIM), like other generalist specialties, has struggled to maintain its identity in the face of mounting sub-specialization over the past few decades. In Canada, the path to licensure for general internists has been through the completion of an extra year of training after three core years of internal medicine. Until very recently, the Royal College of Physicians and Surgeons of Canada (RCPSC) did not recognize GIM as a distinct entity. In response to a societal need to train generalist practitioners who could care for complex patients in an increasingly complex health care setting, the majority of universities across Canada voluntarily developed structured GIM training programs independent of RCPSC recognition. However, interest amongst trainees in GIM was declining, and the GIM workforce in Canada, like that in many other countries, was in danger of serious shortfalls. After much deliberation and consultation, in 2010, the RCPSC recognized GIM as a distinct subspecialty of internal medicine. Since this time, despite the challenges in the educational implementation of GIM as a distinct discipline, there has been a resurgence of interest in this field of medicine. This paper outlines the journey of the Canadian GIM to educational implementation as a distinct discipline, the impact on the discipline, and the implications for the international GIM community.
[Mh] Termos MeSH primário: Medicina Geral/tendências
Medicina Interna/tendências
Internacionalidade
Médicos/tendências
[Mh] Termos MeSH secundário: Canadá
Competência Clínica/normas
Medicina Geral/métodos
Seres Humanos
Medicina Interna/métodos
Médicos/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s11606-016-3891-z


  6 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29400931
[Au] Autor:Butler M
[Ti] Título:AHIMA World Congress. Empowering Members Around the Globe.
[So] Source:J AHIMA;88(1):15-8, 2017 Jan.
[Is] ISSN:1060-5487
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Congressos como Assunto
Gestão da Informação em Saúde
Sociedades
[Mh] Termos MeSH secundário: Seres Humanos
Internacionalidade
Objetivos Organizacionais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:H
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE


  7 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29340519
[Au] Autor:Barboza LA; Ghisi NC
[Ad] Endereço:Laboratório de Biologia Molecular, Universidade Tecnológica Federal do Paraná, Dois Vizinhos, PR, Brasil.
[Ti] Título:Evaluating the current state of the art of Huntington disease research: a scientometric analysis.
[So] Source:Braz J Med Biol Res;51(3):e6299, 2018 Jan 11.
[Is] ISSN:1414-431X
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Huntington disease (HD) is an incurable neurodegenerative disorder caused by a dominant mutation on the 4th chromosome. We aim to present a scientometric analysis of the extant scientific undertakings devoted to better understanding HD. Therefore, a quantitative study was performed to examine the current state-of-the-art approaches that foster researchers' understandings of the current knowledge, research trends, and research gaps regarding this disorder. We performed literature searches of articles that were published up to September 2016 in the "ISI Web of Science™" (http://apps.webofknowledge.com/). The keyword used was "Huntington disease". Of the initial 14,036 articles that were obtained, 7732 were eligible for inclusion in the study according to their relevance. Data were classified according to language, country of publication, year, and area of concentration. The country leader regarding the number of studies published on HD is the United States, accounting for nearly 30% of all publications, followed by England and Germany, who have published 10 and 7% of all publications, respectively. Regarding the language in which the articles were written, 98% of publications were in English. The first publication to be found on HD was published in 1974. A surge of publications on HD can be seen from 1996 onward. In relation to the various knowledge areas that emerged, most publications were in the fields of neuroscience and neurology, likely because HD is a neurodegenerative disorder. Publications written in areas such as psychiatry, genetics, and molecular biology also predominated.
[Mh] Termos MeSH primário: Pesquisa Biomédica/estatística & dados numéricos
Doença de Huntington/genética
[Mh] Termos MeSH secundário: Brasil
Coreia/genética
Seres Humanos
Doença de Huntington/diagnóstico
Doença de Huntington/terapia
Internacionalidade
Linguagem
Complexo Mediador/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (MED12 protein, human); 0 (Mediator Complex)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE


  8 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29397917
[Au] Autor:Lejeune C; Lueza B; Bonastre J; le French costing group
[Ad] Endereço:Université Bourgogne Franche-Comté-Inserm CIC1432, module épidémiologie clinique, 7, boulevard Jeanne-d'Arc, 21000 Dijon, France; Centre hospitalier universitaire, centre d'investigation clinique, module épidémiologie clinique/essais cliniques, 7, boulevard Jeanne-d'Arc, BP 87900, 21000 Dijon, France; Université de Bourgogne et Franche-Comté, EPICAD LNC-UMR1231, 7, boulevard Jeanne-d'Arc, BP 87900, 21000 Dijon, France. Electronic address: catherine.lejeune@u-bourgogne.fr.
[Ti] Título:[Economic analysis of multinational clinical trials in oncology].
[Ti] Título:Analyse économique des essais cliniques internationaux en cancérologie..
[So] Source:Bull Cancer;105(2):204-211, 2018 Feb.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:In oncology, as in other fields of medicine, international multicentre clinical trials came into being so as to include a sufficient number of subjects to investigate a clinical situation. The existence of tight budgetary constraints and the desire to make the best use of the resources available have resulted in the development of economic evaluations associated with these trials, which, thanks to their level of evidence and their size, provide particularly relevant material. Nonetheless, economic evaluations alongside international clinical trials raise specific questions of methodology with regard to both the design and the analysis of the results. Indeed, the costs of goods and services consumed, the types and quantities of resources, and medical practices vary from one country to another and within an individual country. Economic data from the different countries involved must be available so as to study and to take into account this variability, and appropriate techniques for cost estimations and analysis must be implemented to aggregate the results from several countries. From a review of the literature, the aim of this work was to provide an overview of the specific methodological features of economic evaluations alongside international clinical trials: analysis of efficacy data from several countries, collection of resources and real costs, methods to establish the monetary value of resources, methods to aggregate results accounting for the trial effect.
[Mh] Termos MeSH primário: Ensaios Clínicos como Assunto/economia
Internacionalidade
Oncologia/economia
Estudos Multicêntricos como Assunto/economia
[Mh] Termos MeSH secundário: Análise Custo-Benefício
Seres Humanos
Alocação de Recursos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180206
[St] Status:MEDLINE


  9 / 17074 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773449
[Au] Autor:Cajita MI; Denhaerynck K; Dobbels F; Berben L; Russell CL; Davidson PM; De Geest S; BRIGHT study team
[Ad] Endereço:School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
[Ti] Título:Health literacy in heart transplantation: Prevalence, correlates and associations with health behaviors-Findings from the international BRIGHT study.
[So] Source:J Heart Lung Transplant;36(3):272-279, 2017 03.
[Is] ISSN:1557-3117
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Health literacy (HL) is a major determinant of health outcomes; however, there are few studies exploring the role of HL among heart transplant recipients. The objectives of this study were to: (1) explore and compare the prevalence of inadequate HL among heart transplant recipients internationally; (2) determine the correlates of HL; and (3) assess the relationship between HL and health-related behaviors. METHODS: A secondary analysis was conducted using data of the 1,365 adult patients from the BRIGHT study, an international multicenter, cross-sectional study that surveyed heart transplant recipients across 11 countries and 4 continents. Using the Subjective Health Literacy Screener, inadequate HL was operationalized as being confident in filling out medical forms none/a little/some of the time (HL score of 0 to 2). Correlates of HL were determined using backward stepwise logistic regression. The relationship between HL and the health-related behaviors were examined using hierarchical logistic regression. RESULTS: Overall, 33.1% of the heart transplant recipients had inadequate HL. Lower education level (adjusted odds ratio [AOR] 0.24, p < 0.001), unemployment (AOR 0.69, p = 0.012) and country (residing in Brazil, AOR 0.25, p < 0.001) were shown to be associated with inadequate HL. Heart transplant recipients with adequate HL had higher odds of engaging in sufficient physical activity (AOR 1.6, p = 0.016). HL was not significantly associated with the other health behaviors. CONCLUSIONS: Clinicians should recognize that almost one third of heart transplant participants have inadequate health literacy. Furthermore, they should adopt communication strategies that could mitigate the potential negative impact of inadequate HL.
[Mh] Termos MeSH primário: Rejeição de Enxerto/etiologia
Comportamentos Relacionados com a Saúde
Alfabetização em Saúde
Transplante de Coração/métodos
Imunossupressores/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Idoso
Intervalos de Confiança
Estudos Transversais
Feminino
Rejeição de Enxerto/mortalidade
Rejeição de Enxerto/fisiopatologia
Transplante de Coração/efeitos adversos
Transplante de Coração/mortalidade
Seres Humanos
Internacionalidade
Estilo de Vida
Modelos Logísticos
Masculino
Meia-Idade
Determinação de Necessidades de Cuidados de Saúde
Cooperação do Paciente
Prevalência
Prognóstico
Fatores Sexuais
Taxa de Sobrevida
Imunologia de Transplantes
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  10 / 17074 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28460629
[Au] Autor:Reith C; Staplin N; Herrington WG; Stevens W; Emberson J; Haynes R; Mafham M; Armitage J; Cass A; Craig JC; Jiang L; Pedersen T; Baigent C; Landray MJ; SHARP Collaborative Group
[Ad] Endereço:Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK. christina.reith@ndph.ox.ac.uk.
[Ti] Título:Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.
[So] Source:BMC Nephrol;18(1):147, 2017 May 01.
[Is] ISSN:1471-2369
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Reducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of major atherosclerotic events among patients with chronic kidney disease (CKD), with no evidence of an excess risk of cancer or death from any non-vascular cause. However, non-randomized data have suggested that statin therapy may have effects (both adverse and beneficial) on particular non-vascular conditions that do not cause death. METHODS: The Study of Heart and Renal Protection (SHARP) randomized patients with CKD to simvastatin 20 mg plus ezetimibe 10 mg (simvastatin/ezetimibe) daily versus matching placebo. Participants were followed up at least 6 monthly and all post-randomization serious adverse events (SAEs) were recorded. This supplementary analysis reports the effects of treatment on non-vascular SAEs, overall, by system of disease, by baseline characteristics, and by duration of follow-up. RESULTS: During a median of 4.9 years follow-up, similar numbers of participants in the two groups experienced at least one non-vascular SAE (3551 [76.4%] simvastatin/ezetimibe vs 3537 [76.6%] placebo; risk ratio [RR] 0.99, 95% confidence interval [CI] 0.95-1.04). There was no good evidence of any significant effect of simvastatin/ezetimibe on SAEs attributed to any particular nonvascular disease system (of 43 comparisons, only 3 yielded an uncorrected p value < 0.05, of which the smallest was p = 0.02). The relative risk of any nonvascular SAE did not vary significantly among particular prognostic subgroups or by duration of follow-up. CONCLUSIONS: In the SHARP trial, allocation to simvastatin/ezetimibe combination therapy was not associated with any significant non-vascular hazard. TRIALS REGISTRATION: SHARP was retrospectively registered after the first participant was enrolled in 2003 at ISRCTN (ISRCTN54137607 on 31 January 2005: http://www.isrctn.com/ISRCTN54137607) and ClinicalTrials.gov (NCT00125593 on 29 July 2005: https://clinicaltrials.gov/ct2/show/NCT00125593).
[Mh] Termos MeSH primário: LDL-Colesterol/sangue
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/mortalidade
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Hipercolesterolemia/mortalidade
Hipercolesterolemia/prevenção & controle
Insuficiência Renal Crônica/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anticolesterolemiantes/administração & dosagem
Causalidade
Comorbidade
Feminino
Seres Humanos
Hipercolesterolemia/sangue
Incidência
Internacionalidade
Masculino
Meia-Idade
Fatores de Risco
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Cholesterol, LDL); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12882-017-0545-2



página 1 de 1708 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde